Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Durvalumab + Tremelimumab + Gem/Cis in Intrahepatic Cholangiocarcinoma
NCT06017297Phase 2Withdrawn
- Sponsor
- Georgetown University
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Georgetown University. Planned start Dec 2024; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06017297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017297.